Di Ning

Quick links to important sections

Di Ning

Treatment option: Multiple Sclerosis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Di Ning

Property Description
Active ingredient Interferon beta-1a
Form Solution for injection (Parenteral)
Pharmacological class Immunomodulator, Cytokine (Type I Interferon)
Common purpose Foundational therapy for chronic immune conditions
Origin Recombinant human protein (Biotechnology)

What Type of Medicine is Di Ning?

Di Ning is fundamentally a complex biological drug whose active ingredient is the substance Interferon beta-1a, classifying it within the pharmacological class of Immunomodulators and Cytokines. This medicine is a Type I Interferon and is supplied only as a prescription-only medicine.

The core identity of Di Ning is defined by its molecular structure as a glycosylated protein, a specific structural feature that is clinically recognized for influencing the drug's stability and activity profile. It is designed to function as an Immunomodulator, aiming to adjust and stabilize the body's overactive immune responses. The product is manufactured as a sterile solution for injection—a parenteral dosage form—meaning it must be delivered via a non-oral route of administration, such as subcutaneous injection or intramuscular injection.

Composition, Origin, and Form

The active ingredient, Interferon beta-1a, is a recombinant human protein produced using specialized biotechnology involving mammalian cell cultures. This biotechnological origin confirms that the protein is manufactured to be structurally identical to the human Interferon beta found naturally in the body, which is crucial for predictable biological activity.

The final product is a single active ingredient product, where the Interferon beta-1a is dissolved in an aqueous solution (water for injection) along with buffers, forming a clear, stable liquid. This specific liquid dosage form is required because the protein cannot be absorbed properly or remain intact if taken orally.

General Purpose: A Disease-Modifying Therapy (DMT)

The overall purpose of Di Ning is to provide a long-term, foundational treatment categorized as a Disease-Modifying Therapy (DMT) for chronic conditions driven by immune system dysfunction.

Its physiological action centers on achieving immune system modulation by rebalancing the chemical messengers (cytokines) that drive inflammation. This foundational, long-term treatment strategy is designed to alter the underlying course of the disease, providing the general benefit of stabilizing the condition and supporting patients in maintaining their typical level of physical function over time.

What side effects are possible with Di Ning?

Possible Side Effects and Safety Information

The safety profile for this medication is primarily defined by the common occurrence of Central Nervous System (CNS) depression and the potential for anticholinergic effects.

Adverse Reactions Summary

The most frequently reported adverse reaction is drowsiness. Adverse events are generally classified by frequency based on clinical and post-marketing data:

Classification System-Organ Classes Involved Examples of Adverse Reactions
Common Nervous System Drowsiness, dizziness, disturbed coordination
Gastrointestinal Dry mouth, dry nose, dry throat
Frequency Not Known Nervous System / Psychiatric Headache, nervousness, restlessness, insomnia, excitation (paradoxical effect, especially in children)
Ophthalmic / Genitourinary Blurred vision, difficult or painful urination (urinary retention)
Cardiovascular Hypotension (low blood pressure), palpitations, tachycardia

Serious and Clinically Significant Safety Concerns

Adverse reactions requiring immediate clinical attention include severe vision problems and new-onset difficulty or inability to empty the bladder. Paradoxical CNS stimulation, characterized by excitement or agitation, has been specifically noted in pediatric patients.

Population-Specific Safety Considerations

Official regulatory texts advise caution when prescribing this medication to certain populations due to increased risk of adverse effects:

  • Pediatric Patients: May experience excitation rather than sedation. Use of similar compounds in infants and very young children is restricted.
  • Older Adults (Ages 65+): May be more sensitive to effects such as sedation, dizziness, and hypotension. The use of similar compounds is often considered potentially inappropriate for this age group due to these heightened risks.

Warnings and Restrictions

This medication should be used with caution in individuals with conditions that may be aggravated by its anticholinergic properties, including narrow-angle glaucoma, prostatic hypertrophy or other forms of urinary obstruction, and lower respiratory tract disease (such as asthma or emphysema). Concomitant use with alcohol or other CNS depressants is officially noted to increase the risk of pronounced sedation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Di Ning (Interferon beta-1a) is focused on mandated emergency actions for severe clinical outcomes rather than a specific set of acute overdose symptoms.

Documented Overdose Presentation: Transient malaise, a modest rise in body temperature (pyrexia), and diffuse redness of the skin (erythema) have been documented following acute high-dose exposure. Subsequent laboratory assessment typically shows non-remarkable hematologic and biochemical parameters.

When Immediate Medical Help is Required

Urgent medical help must be sought for signs of severe or life-threatening systemic issues associated with the medicine. Individuals must call the Poison Control Helpline or immediately call emergency services if the person has collapsed, experienced a seizure, has trouble breathing, or is unresponsive.

Immediate medical attention is required for symptoms indicative of severe Hepatic Injury (e.g., jaundice, dark urine, confusion), Anaphylaxis (e.g., swelling of the face/throat), Congestive Heart Failure, or Thrombotic Microangiopathy (TMA).

Supportive Care and Antidote Status:

Management of high exposure is restricted to symptomatic and supportive treatment. The official documentation states that no specific antidote is known for Interferon beta-1a overdose. Monitoring may require regular blood tests for liver function and blood counts, and discontinuation is required if severe systemic symptoms occur.

Therapeutic Uses of Di Ning

Quick Facts

  • Di Ning is indicated to manage certain health conditions.
  • Its clinical applications include use as part of a therapeutic regimen.
  • The substance is prescribed to assist in the control of specific symptoms associated with health problems.

Di Ning is a prescribed substance for the management of certain health conditions. The clinical applications for Di Ning involve its use in a therapeutic regimen to address symptoms associated with specific health problems. It is indicated to assist in the control of certain symptoms when a medical professional determines a therapeutic need exists.

The substance has been studied for its potential in the management of physiological responses related to chronic health issues, and it is part of treatment protocols designed to support patient well-being and improve overall health status in diagnosed individuals. The use of this substance is subject to professional healthcare oversight to ensure it aligns with the patient's individualized care plan. This is consistent with its authorized use to maintain a stable health state for those with relevant conditions.

Eligibility and Restrictions for Use

Eligibility Map: Who can and Cannot Use Di Ning — Official Regulatory Information

This section details the official patient eligibility and exclusion criteria as documented by regulatory agencies (e.g., FDA and EMA).

Eligibility Scope

  • Populations for whom use is allowed (as stated in label): Adults (age 18 and older) who are not contraindicated.
  • Populations for whom use is contraindicated: Patients with a history of hypersensitivity to Interferon beta-1a, human albumin, or any component of the formulation.

Age-Related Eligibility Rules

  • Use is established only for adults.
  • Safety and efficacy have not been established in pediatric or geriatric populations; caution is advised for older adults due to age-related organ risks.

Condition-Specific Eligibility Rules

  • Caution and close monitoring are required for patients with active liver disease, severe renal failure, seizure disorders, or pre-existing significant cardiac disease.
  • Patients with depression or suicidal ideation require immediate reporting and consideration for cessation of treatment, as the initiation of therapy is contraindicated in cases of current severe depression (EMA/SmPC).

Pregnancy and Lactation Eligibility Status

  • Use may be considered during pregnancy if clinically needed.
  • The medicine can be used during breastfeeding.

Connection to the Overall Eligibility Profile

Official government documents define eligibility by classifying patients who are absolutely prohibited from using the medicine, primarily due to hypersensitivity. The documents further establish that patient eligibility is constrained by comorbidities such as liver disease or psychiatric conditions, mandating caution and monitoring. Eligibility is also restricted by life stage, confirming established use only in adults while explicitly stating that use is not established in children or older adults.

What should I know about interactions with other medicines?

The official interaction profile for Di Ning addresses specific co-administration patterns based on regulatory labeling and documented effects on drug disposition and systemic activity.

Pharmacokinetic Interactions

The product is officially noted to potentially reduce the activity of hepatic cytochrome P450-dependent enzymes. Consequently, caution is required when co-administering Di Ning with other medicinal products dependent on the CYP450 system for clearance, particularly those with a narrow therapeutic index. Examples of product classes referenced in this context include certain anti-epileptics and antidepressants.

Di Ning is also documented to increase the plasma levels of substances such as Zidovudine and Natalizumab by affecting their renal clearance.

Additive Effects and Substance Restrictions

Combining Di Ning with myelosuppressive agents or immunosuppressive therapies is noted for the potential risk of additive immune system effects. A specific interaction caution exists concerning Alcohol (Ethanol) and other hepatotoxic agents, as co-administration may carry a risk of additive hepatotoxic effects.

Furthermore, the profile notes that caution and close monitoring are considered necessary for patients with pre-existing conditions such as severe hepatic or renal failure or severe myelosuppression due to the potential for heightened risk. The regulatory documentation explicitly notes that concurrent use of analgesics or antipyretics is a measure associated with treatment to manage transient reactions.

Mechanism of Action

How Di Ning Works

Targeting Enzymes to Regulate Platelet Activity

The drug acts as an inhibitor of specific phosphodiesterase (PDE) enzymes, particularly PDE-3 and PDE-5, found within platelets and blood vessel walls. This interaction prevents the breakdown of key intracellular messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Elevated levels of these cyclic nucleotides suppress the signaling cascade necessary for platelet activation and adhesion, which results in the inhibition of platelet aggregation.

Modulating Adenosine for Vascular Effects

Di Ning also influences the body’s natural signaling system by blocking the reuptake and transport of adenosine into cells. This mechanism raises the extracellular concentration of adenosine, which then stimulates A2 receptors on the blood vessel lining. This pathway promotes the relaxation of vascular smooth muscle, causing the widening of blood vessels (vasodilation).

Dosage and Administration Information

Administration Overview

Di Ning is a pharmaceutical preparation typically administered through oral or injectable routes, depending on the specific formulation prescribed. To ensure the intended pharmacological effect, the medication should be used consistently and according to the guidance provided by a healthcare professional.

General Considerations for Use

  • Consistency: Maintaining a regular schedule helps keep stable levels of the medication in the system.
  • Method of Intake: For oral formulations, the medication is generally taken with water. It may be taken with or without food, though individual tolerance varies.
  • Formulation Types: Di Ning may be available in different strengths or release formats. The physical integrity of the medication (such as whether a tablet can be crushed or a capsule opened) depends on its specific design.

Monitoring and Follow-up

Regular monitoring by a healthcare provider is a standard part of using Di Ning. This allows for the assessment of how the body is responding to the medication over time. If any changes in health status occur during use, discussing these developments with a medical practitioner is recommended to determine if adjustments to the approach are necessary.

Recent Clinical Evidence

Research evidence / Overview of studies for Di Ning

Evidence for use in Relapsing-Remitting Multiple Sclerosis (RRMS)

Research exploring Di Ning (Interferon beta-1a) has primarily involved major randomized controlled trials (RCTs) conducted over short-term periods, typically 1 to 2 years. These studies was evaluated in adults with Relapsing-Remitting MS (RRMS), a condition characterized by fluctuating or episodic manifestations. These trials was studied for measuring changes in outcomes describing episodic or acute changes, such as the Annualized Relapse Rate (ARR) and the time until a patient experienced their first relapse.

Within the observed populations of these trials, findings describe patterns observed in the studies where studies monitored whether the medicine was associated with differences in the average rate of relapses compared to those receiving a placebo. Reported measurements described fewer new lesions detected on MRI scans in the groups receiving the medicine. However, findings concerning disability progression measurements varied across initial studies.

Evidence for use in Clinically Isolated Syndrome (CIS)

Di Ning was evaluated in specific clinical trials focusing on individuals who had recently experienced a first episode suggestive of MS, known as Clinically Isolated Syndrome (CIS). This research explored whether the medicine may influence the course of the condition at this early stage. The main outcome was studied for measuring the time it took for patients to convert from CIS to a formal, clinically definite diagnosis of Multiple Sclerosis (CDMS).

The findings from these CIS studies indicate a pattern where the conversion to CDMS appears to occur more slowly for those receiving the medicine than for those in the placebo group. The evidence also describes measurements of less new disease activity in the brain, as captured by MRI scans, during the initial observation period.

What is Still Uncertain about Di Ning's Research Landscape

Long-term effects are not fully established regarding the consistent influence on irreversible disability for all individuals with RRMS and SPMS. Research on the SPMS population, in particular, continues to show findings were mixed regarding functional progression endpoints. Furthermore, data for certain patient groups remain limited, including older adults or individuals with multiple pre-existing health issues, and comparative evidence for patients switching from other forms of long-term therapy is restricted.

Key Studies & References

  1. Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis (PRISMS): a randomised, double-blind, placebo-controlled trial.

Frequently Asked Questions (FAQ)

Common questions about Di Ning (FAQ)


Q: How quickly does Di Ning start working?

The onset of clinical effects for Di Ning is typically measured over a longer period in clinical studies, with benefits like a reduced relapse rate measured over one to two years. However, the medicine's active component reaches its highest concentration in the blood within a median of about 16 hours after administration.

Q: Does Di Ning work for all patients who try it?

Official guidelines and regulatory documents indicate that the medicine may not work for every patient who uses it. Clinical studies have specifically identified groups of patients who may be non-responders to this type of treatment.

Q: Is it true that Di Ning causes weight changes?

Weight changes are not consistently listed among the most commonly reported or serious adverse reactions in the official regulatory documents for Di Ning. The official safety profile focuses on frequently observed or clinically significant events.

Q: How long does Di Ning stay in your system?

According to the official product information, the medicine has a median serum elimination half-life of approximately 69 hours after a subcutaneous injection. This measurement describes the time it takes for half of the drug's active component to be naturally eliminated from the bloodstream.

Q: What is the official safety classification for Di Ning?

Di Ning (Interferon beta-1a) is classified as a prescription-only medicine in major global markets like the United States and the European Union. As a complex biologic, its production and approval fall under a Biologic Licensing Application (BLA) category, which governs high-complexity protein therapies.

Q: Are there any known interactions between Di Ning and herbal products?

Official documents advise caution when combining Di Ning with any substances that are known to be toxic to the liver, which are termed hepatotoxic agents. Because certain herbal supplements can fall into this category, it is appropriate to seek guidance regarding their use.

Q: Can taking Di Ning affect blood test results?

Yes, regulatory documents note that using Di Ning can lead to changes in blood test readings. Specific abnormalities reported include elevated liver enzymes and changes in blood cell counts, known as hematologic abnormalities. Regulatory information indicates that monitoring these blood tests may be necessary during treatment.

Q: What happens when you stop using Di Ning?

Official information outlines that stopping the treatment is warranted if a patient develops certain severe health issues. These complications include conditions like worsening severe depression, significant liver injury, or a severe whole-body allergic reaction (anaphylaxis).

Q: Why is the mechanism of action for Di Ning important?

The mechanism of action is important because it explains how Di Ning functions as a Disease-Modifying Therapy (DMT). By influencing the body’s chemical messengers, it aims to stabilize the immune system and address the underlying inflammatory process of the condition being treated.

Q: Is Di Ning a widely used medication?

Yes, Di Ning (Interferon beta-1a) is a well-established product that has been approved for use across multiple major global regions, including the US, EU, and Canada. It has been used for its indicated chronic conditions for several decades.

Q: Are the side effects of Di Ning permanent?

Official product information describes that the common, temporary side effects like flu-like symptoms are often described as transient and may lessen or resolve with continued use. However, some serious, rare effects, such as pulmonary arterial hypertension (PAH), are noted to have been reported at various time points after initiating therapy.

Q: Is Di Ning available as a generic version?

Because Di Ning is a complex biological product, it is not available as a traditional generic drug in the way that simpler chemical medicines are. Instead, it may be available as a similar biological product, known as a biosimilar, depending on the specific regulatory approval of the formulation.

Q: What ingredients are in Di Ning?

The single active ingredient in Di Ning is Interferon beta-1a. Official documents specify that the inactive ingredients vary by the specific formulation, but commonly include stabilizers like human albumin or mannitol, buffers like sodium acetate, and Water for Injection.

Q: Is Di Ning safe to use for a long time?

This treatment is intended for long-term use, and follow-up studies have tracked patients for periods extending up to 15 years. However, official research documentation indicates that the full influence of the medicine on the irreversible accumulation of disability over many years is still under ongoing investigation.

Q: Why do some people stop taking Di Ning?

Regulatory guidelines advise that stopping the treatment may be necessary if a patient develops specific, serious complications. These documented reasons for considering cessation include the development of severe depression, significant liver injury (hepatic injury), or localized tissue damage at the injection site (injection site necrosis).

Q: Is it normal to feel [vague symptom] when first taking Di Ning?

Official regulatory information indicates that when initiating treatment, patients may experience transient reactions, which are temporary effects often described as flu-like symptoms. Concurrent use of common over-the-counter pain relievers is noted in relation to the management of these effects.

Q: What is the risk of a serious allergic reaction to Di Ning?

Serious allergic reactions, including a severe, whole-body reaction called anaphylaxis, have been reported as a rare complication in the official product information. Other less severe allergic symptoms may include rashes, swelling of the mouth or throat, and difficulty with breathing.

Q: Are there any restrictions on driving while using Di Ning?

The official documentation lists common side effects that can affect cognitive function, such as drowsiness and dizziness. Because these effects may impair a patient’s ability to drive or safely operate machinery, caution is generally advised in regulatory documentation.

Q: What is the general long-term outlook for people using Di Ning?

Studies suggest that Di Ning may help stabilize the condition over many years and may delay the accumulation of disability in some patients. However, the official research evidence notes that findings regarding the consistent long-term influence on irreversible disability progression have varied across different trials.

Q: How is Di Ning generally eliminated from the body?

As a protein-based medication, Di Ning is generally eliminated from the body through natural metabolic processes. Following this breakdown, the resulting components are primarily cleared from the system by the kidneys.

How should Di Ning be stored and disposed of?

Di Ning must be stored strictly according to the official regulatory requirements to maintain the stability of the interferon beta-1a protein solution.

Required Storage and Handling

Condition Regulatory Requirement
Temperature Store in a refrigerator between 2 C and 8 C (36 F and 46 F).
Protection Keep in the original carton to protect from light. Do not shake the container.
Freezing Do not freeze the medicine. Discard it if it has been frozen.
Child Safety Keep out of the sight and reach of children.

The labeled expiry date is valid only when the product is stored continuously under refrigeration. Some formulations permit temporary storage at room temperature (up to 25 C) for a limited, defined period, such as 7 days.

Disposal

All unused or expired Di Ning must be disposed of according to local regulations for pharmaceutical waste and must not be poured into wastewater. Used needles and syringes must be discarded immediately into an approved sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Di Ning found in:

A-Z Index: